Misplaced Pages

Revision as of 02:32, 25 January 2012

Finasteride

Clinical data
Trade names	Proscar
AHFS/Drugs.com	Monograph
MedlinePlus	a698016
Pregnancy category	X (will cause birth defects in an unborn baby)
Routes of administration	Oral
ATC code	G04CB01 (WHO) D11AX10 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Bioavailability	63%
Metabolism	Hepatic
Elimination half-life	Elderly: 8 hours Adults: 6 hours
Excretion	Feces (57%) and urine (39%) as metabolites
Identifiers
IUPAC name N-(1,1-dimethylethyl)-3-oxo- (5α,17β)-4-azaandrost-1-ene-17-carboxamide
CAS Number	98319-26-7
PubChem CID	57363
DrugBank	APRD00632
ChemSpider	51714
UNII	57GNO57U7G
KEGG	D00321
ChEBI	CHEBI:5062
ChEMBL	ChEMBL710
CompTox Dashboard (EPA)	DTXSID3020625
ECHA InfoCard	100.149.445
Chemical and physical data
Formula	C23H36N2O2
Molar mass	372.549 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES O=C(NC(C)(C)C)21(CC3(1CC2)CC4NC(=O)\C=C/34C)C
InChI InChI=1S/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1 Key:DBEPLOCGEIEOCV-WSBQPABSSA-N
(what is this?)  (verify)

Finasteride (brand names Proscar and Propecia by Merck, among other generic names) is a synthetic 5-alpha-reductase inhibitor, an inhibitor of the enzyme that converts testosterone to dihydrotestosterone (DHT). Finasteride is approved for the treatment of benign prostatic hyperplasia (BPH) and male pattern baldness (MPB).

Medical uses

Benign prostatic hyperplasia

Physicians use finasteride for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate. The approved dose is 5 mg once a day, and 6 months or more of treatment with finasteride may be required to determine the therapeutic results of treatment. If the drug is discontinued, any therapeutic benefits will be reversed. Finasteride may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow.

Male pattern baldness

In a 5-year study of men with mild to moderate hair loss, 2 out of 3 of the men who took 1 mg of finasteride daily regrew some hair, as measured by hair counts. In contrast, all of the men in the study who were not taking finasteride lost hair. In the same study, based on photographs that were reviewed by an independent panel of dermatologists, 48% of those treated with finasteride experienced visible regrowth of hair, and a further 42% had no further loss. Average hair count in the treatment group remained above baseline, and showed an increasing difference from hair count in the placebo group, for all five years of the study. Finasteride is effective only for as long as it is taken; the hair gained or maintained is lost within 6–12 months of ceasing therapy. In clinical studies, finasteride, like minoxidil, was shown to work on both the crown area and the hairline, but is most successful in the crown area.

Some users, in an effort to save money, buy Proscar (finasteride 5 mg) instead of Propecia, and split the Proscar pills into several parts to approximate the Propecia dosage. The pills are coated to prevent contact with the active ingredient during handling, and the dust or crumbs from broken Proscar tablets should be kept away from pregnant women or women who may become pregnant.

Adverse effects

Side effects of finasteride include impotence (1.1% to 18.5%), abnormal ejaculation (7.2%), decreased ejaculatory volume (0.9% to 2.8%), abnormal sexual function (2.5%), gynecomastia (2.2%), erectile dysfunction (1.3%), ejaculation disorder (1.2%) and testicular pain. According to the product package insert, resolution occurred in men who discontinued therapy with finasteride due to these side effects and in most men who continued therapy. The PPI also states that patients have reported persisting erectile dysfunction despite discontinuing the drug. In December 2010, Merck added depression as a side effect of finasteride. In October 2011, Merck shut down both the Propecia and Proscar product webpages and replaced the existing text with a message encouraging patients to report any negative side effects to the FDA.

Prostate cancer

The FDA has added warning to finasteride about an increased risk of high-grade prostate cancer. Whilst the potential for positive, negative or neutral changes to the potential risk of developing prostate cancer with finasteride has not been established, evidence has suggested it may temporarily reduce the growth and prevalence of benign prostate tumors, but could also mask the early detection of prostate cancer. The primary area for concern is for patients who may develop prostate cancer whilst taking finasteride for benign prostatic hyperplasia, which in turn could delay diagnosis and early treatment of the prostate cancer, thereby potentially increasing the risk of these patients developing high-grade prostate cancer.

The 2005 Prostate Cancer Prevention Trial (PCPT) showed at a dosage of 5 mg per day, as is commonly prescribed for BPH, participants taking finasteride were 25% less likely to have developed prostate cancer at the end of the trial compared to those taking a placebo. It appeared (incorrectly) that finasteride increased the specificity and selectivity of prostate cancer detection, thus creating an apparently increased rate of high Gleason grade tumor. A 2008 update of this study found that finasteride reduces the incidence of prostate cancer by 30%. In the original study, it turns out that the smaller prostate caused by finasteride means that a doctor is more likely to hit upon cancer nests and more likely to find aggressive looking cells. Most of the men in the study who had both low and high-grade prostate cancer chose to be treated, and many had their prostates removed. A pathologist then carefully examined each of those 500 prostates and compared the kinds of cancers found at surgery to those initially diagnosed at biopsy. This study concluded that finasteride did not increase the risk of high-grade prostate cancer.

Sexual side effects

There have been case reports of persistent diminished libido or erectile dysfunction, even after stopping the drug. In December 2008, the Swedish Medical Products agency concluded a safety investigation of finasteride and subsequently advised that the use of finasteride may result in irreversible sexual dysfunction. The Agency's updated safety information lists difficulty in obtaining an erection that persists indefinitely, even after the discontinuation of finasteride, as a possible side effect of the drug. The UK's Medical and Healthcare Products Regulatory Agency (MHRA) say that erectile dysfunction that persists once use of finasteride has stopped has been reported to them. Similar labeling changes have been made by the Italian government. For a period of time there was a discrepancy between European and North American warning labels regarding the risks of developing persistent sexual side effects from taking Propecia but after two years Merck revised the United States' warning in consumer and medical leaflets to include erectile dysfunction that may persist after stopping finasteride.

Male breast cancer

In December 2009, the Medicines and Healthcare products Regulatory Agency in the UK announced new drug safety advice on finasteride and the potential risk of male breast cancer. The agency concluded that, although overall incidence of male breast cancer in clinical trials for finasteride 5 mg was not significantly increased, a higher risk of male breast cancer with finasteride use cannot be excluded. A warning on this risk will be included in the product information. Merck revised the United States' warning in consumer and medical leaflets to include the risk of male breast cancer.

Teratogenicity

Finasteride is in the FDA pregnancy category X. This means that it is known to cause birth defects in an unborn baby. Women who are or who may become pregnant must not handle crushed or broken finasteride tablets, because the medication could be absorbed through the skin. Finasteride is known to cause birth defects in a developing male baby. Exposure to whole tablets should be avoided whenever possible, however exposure to whole tablets is not expected to be harmful as long as the tablets are not swallowed. It is not known whether finasteride passes into breast milk, and thus should not be taken by breastfeeding women. Finasteride may pass into the semen of men, but Merck states that a pregnant woman's contact with the semen of a man taking finasteride is not an issue for concern. Finasteride is known to affect blood donations, and potential donors are typically restricted for at least a month after their most recent dose.

Interference with doping assays

Many sports organizations have banned finasteride because it can be used to mask steroid abuse. Since 2005, finasteride has been on the World Anti-Doping Agency's list of banned substances. However, it was removed from the list in 2009. Notable athletes who used finasteride for hair loss and were banned from international competition include skeleton racer Zach Lund, bobsledder Sebastien Gattuso, footballer Romário and ice hockey goaltender José Théodore.

Mechanism of action

Testosterone in males is produced primarily in the testicles, but also in the adrenal glands. The majority of testosterone in the body is bound to sex hormone-binding globulin (SHBG), a protein produced in the liver that transports testosterone in the bloodstream, prevents its metabolism, and prolongs its half-life. Once it becomes unbound from SHBG, free testosterone can enter cells throughout the body. In certain tissues, notably the scalp, skin, and prostate, testosterone is converted into dihydrotestosterone (DHT) by the enzyme 5-alpha reductase. DHT is a more powerful androgen than testosterone (as it has a much higher affinity for the androgen receptor), so 5-alpha reductase can be thought to amplify the androgenic effect of testosterone in the tissues in which it's found. In addition to blocking the 5-alpha reductase enzyme, finasteride is a competitive inhibitor of the 5-beta reductase type 2 enzyme.

Finasteride is an inhibitor of 5-alpha reductase by being an aza analog of testosterone, thereby initially binding to 5-alpha reductase similarly to testosterone, but with the effect of remaining bound to it rather than being converted, thereby blocking the space that testosterone would otherwise have taken. By blocking 5-alpha reductase, finasteride blocks the conversion of testosterone into the more powerful androgen DHT. This reduces androgenic activity in the scalp, treating hair loss at its hormonal source. In the prostate, inhibition of 5-alpha reductase leads to a reduction of prostate volume, which improves the symptoms of benign prostatic hyperplasia (BPH) and reduces the risk of prostate cancer. Inhibition of 5-alpha reductase also leads to a reduction in the weight of the epididymis and a decrease in the percentage of motile and morphologically normal spermatozoa found in the epididymis.

By inhibiting 5AR in the central nervous system, finasteride has been shown to diminish the biosynthesis of neurosteroids, which require 5AR function. Neurosteroids and neuroactive steroids play a role in memory enhancement, sedative, hypnotic, anesthetic, anxiolytic, antistress, sleep modulating, anticonvulsant, and antidepressant properties. It has therefore been suggested that alterations in neurosteroid levels explain some of the mental and sexual side-effects of finasteride.

Preparations

Drug trade names include Propecia and Proscar, the former marketed for male pattern baldness (MPB) and the latter for benign prostatic hyperplasia (BPH), both are products of Merck & Co. There is 1 mg of finasteride in Propecia and 5 mg in Proscar. Merck's patent on finasteride for the treatment of BPH expired on June 19, 2006. Merck was awarded a separate patent for the use of finasteride to treat MPB. This patent is set to expire in November 2013.

Some studies have shown that the dose of finasteride needed to treat male pattern baldness may be smaller than 1 mg. Petitions to the FDA to re-examine the approved dosage in light of the statistical evidence and possible long-term risks, were met with the response that a study had shown increased effect of a 1 mg dose compared to 0.2 mg without added risks; the same study also concluded that doses of 0.01 mg per day were found to be ineffective in treating hair loss.

Chemical synthesis

Finasteride is synthesized from progesterone:

History

In 1974, Julianne Imperato-McGinley of Cornell Medical College in New York attended a conference on birth defects. She reported on a group of hermaphroditic children in the Caribbean who appeared sexually ambiguous at birth, and were initially raised as girls, but then grew external male genitalia and other masculine characteristic post-onset of puberty. Her research group found that these children shared a genetic mutation, causing deficiency of the 5-alpha reductase enzyme and male hormone dihydrotestosterone (DHT), which was found to have been the etiology behind abnormalities in male sexual development. Upon maturation, these individuals were observed to have smaller prostates which were underdeveloped, and were also observed to lack incidence of male pattern baldness.

In 1975, copies of Imperato-McGinley's presentation were seen by P. Roy Vagelos, who was then serving as Merck's basic-research chief. He was intrigued by the notion that decreased levels of DHT led to the development of smaller prostates. Dr. Vagelos then sought to create a drug which could mimic the condition found in the pseudo-hermaphroditic children in order to treat older men who were suffering from benign prostatic hyperplasia.

In 1992, finasteride (5 mg) was approved by the U.S. Food and Drug Administration (FDA) for treatment of benign prostatic hyperplasia (BPH), which Merck marketed under the brand name Proscar.

In 1997, Merck was successful in obtaining FDA approval for a second indication of finasteride (1 mg) for treatment of male pattern baldness (MPB), which was marketed under the brand name Propecia.

See also

• Dutasteride, related 5-alpha reductase inhibitor.

References

1. Edwards, Jayne E; Moore, R Andrew (2002). "Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials". BMC Urology. 2: 14. doi:10.1186/1471-2490-2-14. PMC 140032. PMID 12477383.{{cite journal}}: CS1 maint: unflagged free DOI (link)
2. Rossi S (Ed.) (2004). Australian Medicines Handbook 2004. Adelaide: Australian Medicines Handbook. ISBN 0-9578521-4-2.
3. Leyden, James; Dunlap, Frank; Miller, Bruce; Winters, Peter; Lebwohl, Mark; Hecker, David; Kraus, Stephen; Baldwin, Hilary; Shalita, Alan (1999). "Finasteride in the treatment of men with frontal male pattern hair loss". Journal of the American Academy of Dermatology. 40 (6 Pt 1): 930–7. doi:10.1016/S0190-9622(99)70081-2. PMID 10365924.
4. Morrow, David J. (March 19, 1999). "New Profits in Old Bottles; Companies Find Bonus in Drugs That Cure Several Ills". The New York Times. Retrieved June 6, 2010. {{cite news}}: Italic or bold markup not allowed in: |publisher= (help)
5. "Patient Information About Proscar" (PDF). Merck Sharp & Dohme Corp.
6. Drugs.com | Propecia Side Effects
8. 5-alpha reductase inhibitors (5-ARIs): Label Change - Increased Risk of Prostate Cancer | U.S. Department of Health & Human Services
9. Walsh, PC (2010 Apr 1). "Chemoprevention of prostate cancer". The New England journal of medicine. 362 (13): 1237–8. doi:10.1056/NEJMe1001045. PMID 20357287. {{cite journal}}: Check date values in: |date= (help)
10. "Can Prostate Cancer Be Prevented?" American Cancer Society, May 25, 2005.
11. Gina Kolata (June 15, 2008). "New Take on a Prostate Drug, and a New Debate". NY Times. Retrieved 2008-06-15.
12. Redman, M. W.; Tangen, C. M.; Goodman, P. J.; Lucia, M. S.; Coltman, C. A.; Thompson, I. M. (2008). "Finasteride Does Not Increase the Risk of High-Grade Prostate Cancer: A Bias-Adjusted Modeling Approach". Cancer Prevention Research. 1 (3): 174–81. doi:10.1158/1940-6207.CAPR-08-0092. PMC 2844801. PMID 19138953.
13. ^ Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML (201). "Adverse Side Effects of 5α-Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients". J Sex Med. 8 (3): 872–884. doi:10.1111/j.1743-6109.2010.02157.x. PMID 21176115. {{cite journal}}: Unknown parameter |laysummary= ignored (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
14. Package Leaflet Information for the User, Swedish package insert for Propecia 1mg
15. MHRA PUBLIC ASSESSMENT REPORT | The risk of male breast cancer with finasteride
16. ^ PROPECIA® (finasteride) | Merck & Co., Inc.
17. "MHRA drug safety advice: Finasteride and potential risk of male breast cancer". 4 December 2009. Retrieved 4 December 2009.
18. "FDA guidance on blood donors and medications" (PDF). U.S. Food and Drug Administration. Archived from the original (pdf) on October 31, 2005. Retrieved 01-02-2009. {{cite web}}: Check date values in: |accessdate= (help)
19. Sandomir, Richard (2006-01-19). "Skin Deep; Fighting Baldness, and Now an Olympic Ban". The New York Times. Retrieved 2010-05-02.
20. World Anti-Doping Agency Q&A: Status of Finasteride
21. "Theodore's hair tonic causes positive test". TSN. 2006-02-10. Retrieved 2006-07-22.
22. PMID 19515843
23. Robaire, B; Henderson, N (2006). "Actions of 5α-reductase inhibitors on the epididymis". Molecular and Cellular Endocrinology. 250 (1–2): 190–5. doi:10.1016/j.mce.2005.12.044. PMID 16476520.
24. Primary Patent Expirations for Selected High Revenue Drugs
25. fda.gov | Patent Expiration for Propecia
26. "Center for Drug Evaluation and Research, Application Number NDA 20-788" (PDF). U.S. Food and Drug Administration.
27. ^ "Letter to Dr. Sherman Frankel, University of Pennsylvania" (PDF). U.S. Food and Drug Administration.
28. Rasmusson, Gary H.; Reynolds, Glenn F.; Steinberg, Nathan G.; Walton, Edward; Patel, Gool F.; Liang, Tehming; Cascieri, Margaret A.; Cheung, Anne H.; Brooks, Jerry R. (1986). "Azasteroids: structure-activity relationships for inhibition of 5.alpha.-reductase and of androgen receptor binding". Journal of Medicinal Chemistry. 29 (11): 2298–315. doi:10.1021/jm00161a028. PMID 3783591.
29. Bhattacharya, Apurba.; Dimichele, Lisa M.; Dolling, Ulf H.; Douglas, Alan W.; Grabowski, Edward J. J. (1988). "Silylation-mediated oxidation of 4-aza-3-ketosteroids with DDQ proceeds via DDQ-substrate adducts". Journal of the American Chemical Society. 110: 3318. doi:10.1021/ja00218a062.
30. 5-Alpha-Reductase Deficiency | WebMD
31. Dutasteride | Clinical Trials | International Society of Hair Restoration Surgery
32. Freudenheim, Milt (February 16, 1992). "Keeping the Pipeline Filled at Merck". The New York Times.

External links

• Proscar | Official website
• Propecia | Official website

• 5-alpha-reductase inhibitors
• Lactams